The participation of Swiss Rockets AG, together with Torpedo Pharmaceuticals AG and Rocket Isotopes AG, at the Theranostics World Congress marked a truly outstanding moment for the group – and a powerful statement of intent within the global theranostics community.
Across all days of the congress, the Swiss Rockets booth became a vibrant meeting point for the industry. The team engaged in a good number of high-quality conversations, resulting in a wealth of new and highly promising contacts from across the radiopharmaceutical ecosystem. Leaders from industry, clinicians, and isotope experts stopped by, alongside many familiar faces from research and science – and just as many inspiring new ones. The atmosphere was open, curious, and forward-looking, reflecting the momentum currently shaping the field.
What stood out most was the depth of discussion. Conversations went far beyond surface-level interest, quickly moving into detailed exchanges on next-generation isotopes, clinical translation, supply-chain resilience, and the future of radioligand therapies. The integrated approach of Torpedo and Rocket Isotopes – spanning biology, chemistry, and isotope access – resonated strongly with an audience that understands both the promise and the complexity of theranostics.
A Moonshot Moment: Vladimir Cmiljanovic on the Global Stage
A defining highlight of the Theranostics World Congress was the keynote address by Vladimir Cmiljanovic, CEO of Swiss Rockets AG, delivered to a truly international audience of scientists, clinicians, and industry leaders.
In a powerful and deeply personal speech, Vladimir articulated what he described as Swiss Rockets’ Moonshot: a lifelong commitment to fundamentally changing how cancer is treated. Drawing on his own childhood experience – the loss of his grandmother to leukaemia – he shared the promise he once made as a five-year-old: “One day, I will cure cancer.” At TWC, that promise was reframed not as a slogan, but as a guiding mission that has shaped the vision, structure, and ambition of Swiss Rockets.
A particularly moving and symbolic moment occurred at the booth when the daughter of Saul Hertz paid a visit. Saul Hertz, widely regarded as the father of Theranostics, pioneered the medical use of artificially produced radionuclides and developed the first targeted cancer therapies using radioactive iodine. His work laid the foundation for combining diagnostic imaging and therapy into a single, unified concept – an idea that continues to shape the field today.
The presence of Swiss Rockets, Torpedo Pharmaceuticals, and Rocket Isotopes at the Theranostics World Congress was not only a commercial and scientific success – it was a moment of connection between past, present, and future. It underscored a shared ambition within the community: to push the boundaries of precision medicine, grounded in scientific rigor, collaboration, and long-term vision.
The congress left the team energized, inspired, and deeply encouraged by the quality of dialogue and the openness of the global theranostics community. The conversations started in those few days will clearly extend far beyond the congress itself.